Welcome to LookChem.com Sign In|Join Free

CAS

  • or

86847-87-2

Post Buying Request

86847-87-2 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

86847-87-2 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 86847-87-2 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 8,6,8,4 and 7 respectively; the second part has 2 digits, 8 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 86847-87:
(7*8)+(6*6)+(5*8)+(4*4)+(3*7)+(2*8)+(1*7)=192
192 % 10 = 2
So 86847-87-2 is a valid CAS Registry Number.

86847-87-2SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 16, 2017

Revision Date: Aug 16, 2017

1.Identification

1.1 GHS Product identifier

Product name 2,2-Dimethyl-N-(6-fluoro-2-pyridinyl)propanamide

1.2 Other means of identification

Product number -
Other names N-(6-fluoro-2-pyridinyl)-2,2-dimethylpropanamide

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:86847-87-2 SDS

86847-87-2Downstream Products

86847-87-2Relevant articles and documents

Rhodium(III)-catalyzed oxidative olefination of pyridines and quinolines: Multigram-scale synthesis of naphthyridinones

Zhou, Jun,Li, Bo,Hu, Fang,Shi, Bing-Feng

supporting information, p. 3460 - 3463 (2013/07/26)

A Rh(III)-catalyzed oxidative olefination of pyridines and quinolines has been achieved. This method has a broad substrate scope and has been applied to the expeditious, multigram-scale synthesis of naphthyridinones.

Constrained compounds as CGRP-receptor antagonists

-

Page/Page column 60, (2008/06/13)

The invention encompasses constrained bicyclic and tricyclic CGRP-receptor antagonists, methods for identifying them, pharmaceutical compositions comprising them, and methods for their use in therapy for treatment of migraine and other headaches, neurogenic vasodilation, neurogenic inflammation, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), and other conditions the treatment of which can be effected by the antagonism of CGRP-receptors.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 86847-87-2